Search Results - "Ziglioli, Nicoletta"

Computational reactive–diffusive modeling for stratification and prognosis determination of patients with breast cancer receiving Olaparib by Schettini, Francesco, De Bonis, Maria Valeria, Strina, Carla, Milani, Manuela, Ziglioli, Nicoletta, Aguggini, Sergio, Ciliberto, Ignazio, Azzini, Carlo, Barbieri, Giuseppina, Cervoni, Valeria, Cappelletti, Maria Rosa, Ferrero, Giuseppina, Ungari, Marco, Locci, Mariavittoria, Paris, Ida, Scambia, Giovanni, Ruocco, Gianpaolo, Generali, Daniele

“…Mathematical models based on partial differential equations (PDEs) can be exploited to handle clinical data with space/time dimensions, e.g. tumor growth…”
Get full text

Clinical, Radiometabolic and Immunologic Effects of Olaparib in Locally Advanced Triple Negative Breast Cancer: The OLTRE Window of Opportunity Trial by Schettini, Francesco, Corona, Silvia Paola, Giudici, Fabiola, Strina, Carla, Sirico, Marianna, Bernocchi, Ottavia, Milani, Manuela, Ziglioli, Nicoletta, Aguggini, Sergio, Azzini, Carlo, Barbieri, Giuseppina, Cervoni, Valeria, Cappelletti, Maria Rosa, Molteni, Alfredo, Lazzari, Maria Chiara, Ferrero, Giuseppina, Ungari, Marco, Marasco, Elena, Bruson, Alice, Xumerle, Luciano, Zago, Elisa, Cerra, Davide, Loddo, Marco, Williams, Gareth H, Paris, Ida, Scambia, Giovanni, Generali, Daniele

“…Olaparib is effective in metastatic triple negative breast cancer (TNBC) carrying germline mutations in DNA damage repair (DDR) genes (g -mut). The OLTRE…”
Get full text

Tumor Type Agnostic Therapy Carrying BRAF Mutation: Case Reports and Review of Literature by Bernocchi, Ottavia, Sirico, Marianna, Corona, Silvia Paola, Strina, Carla, Milani, Manuela, Cappelletti, Maria Rosa, Ferrero, Giuseppina, Ziglioli, Nicoletta, Cervoni, Valeria, Macchiavelli, Andrea, Roviello, Giandomenico, Generali, Daniele

“…Precision medicine is based on molecular and genotypic patient characterization to define specific target treatment. BRAF mutation is an oncogenic driver, and…”
Get full text

Assessing the long-term prognostic ability of the 70 gene expression signature MammaPrint in an Italian single-center prospective cohort study of early-stage intermediate-risk breast cancer patients by Generali, Daniele, Rocca, Andrea, Strina, Carla, Milani, Manuela, Fiorino, Enrico, Cervoni, Valeria, Azzini, Carlo, Saracino, Antonella, Ciliberto, Ingnazio, Ziglioli, Nicoletta, Alberio, Marzia, Giudici, Fabiola, Dester, Martina, Ciani, Oriana, Fornaro, Giulia, Aguggini, Sergio, Dreezen, Christa, Pronin, Darina, Ende, Stefanie

“…The aim of this study was to assess the prognostic performance of the 70-gene signature, MammaPrint, in an Italian single-center prospective cohort of…”
Get full text

Addendum: Impact of BMI on the outcome of metastatic breast cancer patients treated with everolimus: a retrospective exploratory analysis of the BALLET study by Corona, Silvia P, Giudici, Fabiola, Jerusalem, Guy, Ciruelos, Eva, Strina, Carla, Sirico, Marianna, Bernocchi, Ottavia, Milani, Manuela, Dester, Martina, Ziglioli, Nicoletta, Barbieri, Giuseppina, Cervoni, Valeria, Montemurro, Filippo, Generali, Daniele

Get full text

Impact of BMI on the outcome of metastatic breast cancer patients treated with everolimus: a retrospective exploratory analysis of the BALLET study by Corona, Silvia P., Giudici, Fabiola, Jerusalem, Guy, Ciruelos, Eva, Strina, Carla, Sirico, Marianna, Bernocchi, Ottavia, Milani, Manuela, Dester, Martina, Ziglioli, Nicoletta, Barbieri, Giuseppina, Cervoni, Valeria, Montemurro, Filippo, Generali, Daniele

“…INTRODUCTIONReliable biomarkers of response to mTOR inhibition are yet to be identified. As mTOR is heavily implicated in cell-metabolism, we investigated the…”
Get full text

Early Changes of the Standardized Uptake Values (SUV max ) Predict the Efficacy of Everolimus-Exemestane in Patients with Hormone Receptor-Positive Metastatic Breast Cancer by Sirico, Marianna, Bernocchi, Ottavia, Sobhani, Navid, Giudici, Fabiola, Corona, Silvia P, Vernieri, Claudio, Nichetti, Federico, Cappelletti, Maria Rosa, Milani, Manuela, Strina, Carla, Cervoni, Valeria, Barbieri, Giuseppina, Ziglioli, Nicoletta, Dester, Martina, Bianchi, Giulia Valeria, De Braud, Filippo, Generali, Daniele

“…The mTORC1 inhibitor everolimus has been approved in combination with the aromatase inhibitor exemestane for the treatment of hormone receptor-positive (HR+)…”
Get full text

Tumor Type Agnostic Therapy Carrying BRAF Mutation: Case Reports and Review of Literature by Bernocchi, Ottavia, Sirico, Marianna, Corona, Silvia Paola, Strina, Carla, Milani, Manuela, Cappelletti, Maria Rosa, Ferrero, Giuseppina, Ziglioli, Nicoletta, Cervoni, Valeria, Macchiavelli, Andrea, Roviello, Giandomenico, Generali, Daniele

“…BACKGROUNDPrecision medicine is based on molecular and genotypic patient characterization to define specific target treatment. BRAF mutation is an oncogenic…”
Get full text